Kayela Arrotta

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Kayela Arrotta sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting upper half by trial count

Kayela Arrotta: 2 sponsored US clinical trials, 2 recruiting.

Kayela Arrotta sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. The most-studied condition in this pipeline is Epilepsy, with 2 trials.

Mid-pack sponsor footprint

Kayela Arrotta is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING NA

Readiness Brain Operation Optimization Training (ReBOOT) for Epilepsy Surgery

NCT05992402
RECRUITING NA

Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy)

NCT05954182

Therapeutic Areas

Epilepsy 2

What is open in the Kayela Arrotta pipeline

2 recruiting of 2 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Epilepsy (2 trials), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kayela Arrotta: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Kayela Arrotta sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Kayela Arrotta1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Kayela Arrotta sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kayela Arrotta sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kayela Arrotta page

2 registered trials is a research-attention snapshot, not an endorsement of Kayela Arrotta or any single study.

  • 2 of Kayela Arrotta's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Epilepsy is the condition Kayela Arrotta studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epilepsy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kayela Arrotta pipeline card: 2 registered trials from official public datasets.Report a data error.